SLU-PP-332
SLU-PP-332 (ERRα Agonist)
A small molecule ERRα agonist that activates mitochondrial biogenesis pathways similar to endurance exercise. Nicknamed a "molecular exercise mimetic."
SLU-PP-332 is not approved by the FDA for human use. It is sold strictly for research purposes only and is not intended for human consumption, diagnosis, treatment, or prevention of any disease or condition. Purchase and use is entirely at your own risk.
Sourcing for research purposes?
View at Ascension Peptides →What it is
SLU-PP-332 is a synthetic small molecule developed at St. Louis University (hence the "SLU" designation). It is a potent agonist of ERRα (Estrogen-Related Receptor alpha) — a nuclear receptor that acts as a master regulator of mitochondrial biogenesis and oxidative metabolism.
ERRα controls genes involved in fatty acid oxidation, oxidative phosphorylation, and mitochondrial function. Activating it pharmacologically mimics some of the cellular adaptations that occur during endurance exercise — particularly the shift toward fat as fuel and the expansion of mitochondrial capacity.
It is technically a small molecule compound rather than a peptide, but is frequently discussed alongside peptides in the performance and longevity research space.
What research shows
- Approximately 70% improvement in running endurance in sedentary mice in a widely-cited early study
- Activation of genes involved in mitochondrial biogenesis via the PGC-1α pathway
- Increased fatty acid oxidation — shifts energy utilization toward fat burning
- Reduced fat mass in obese animal models alongside improved metabolic markers
- Cardiac benefits in some models — improved heart function through enhanced mitochondrial efficiency
What remains unknown
- Human safety and efficacy — no published human clinical trials exist as of 2025
- Optimal human dosing — rodent doses do not translate directly to human equivalents
- Long-term safety profile — effects of sustained ERRα activation are not characterized
- Whether exercise and SLU-PP-332 combined produce additive or redundant benefits
- Cancer risk implications — ERRα overexpression has been documented in some cancer types
Administration basics
Common use cases
Endurance enhancement, metabolic optimization, mitochondrial health. Primarily of interest to longevity and performance researchers.
Half-life
Not well-established in humans. Rodent studies suggest a short half-life requiring regular dosing.
Administration
Subcutaneous injection most common in community use. Oral research is ongoing but bioavailability is limited in current formulations.
Source this compound
Looking for SLU-PP-332?
Ascension Peptides is a third-party research compound vendor. We link to them as an affiliate — if you purchase through our link we may earn a commission at no cost to you. All compounds are sold for research purposes only and are not intended for human use.
View at Ascension PeptidesResearch Protocols & Common Usage
Doses used in research
- Rodent studies used 30mg/kg — this does not translate to human dosing
- No established human dose exists; any community protocols are entirely experimental
- Anecdotal reports of 5–20mg subcutaneous doses exist but have no established safety basis
Administration routes studied
Typical protocol duration
Unknown. Animal studies typically ran 2–4 weeks. Long-term protocols have no research basis.
Common stacking protocols
- SLU-PP-332 + MOTS-c — combined for broad mitochondrial and exercise-mimetic effects
- SLU-PP-332 + SS-31 — combined for mitochondrial optimization in longevity protocols
- SLU-PP-332 + NAD+ precursors (NMN/NR) — stacked for comprehensive mitochondrial support
- SLU-PP-332 + Ipamorelin/CJC-1295 — combined with GH peptides in performance protocols
Contraindications & combinations to avoid
- History of cancer or high cancer risk — ERRα is overexpressed in certain cancers; implications of pharmacological activation are unknown
- No established contraindication profile exists given the complete absence of human trial data
- Pregnancy and breastfeeding — no safety data; strongly avoid
- Cardiovascular disease — cardiac effects of ERRα activation at pharmacological doses are not characterized in humans
Dosing information reflects doses used in published research and commonly reported community protocols only. This is not a personal recommendation. These compounds are not FDA-approved for human use in the contexts described. Consult a qualified healthcare provider before starting any protocol.
Considering stacking?
See the stacking guide for common combinations with SLU-PP-332 and what to avoid.
Track your SLU-PP-332 protocol
Log your experience, track outcomes over time, and get AI-powered interpretation of your results after 14 days of data. Private, $14.99/month.
Start trackingGet research updates
We'll notify you when we update the SLU-PP-332 page or publish related research.
More in the library
Community Reviews
Reviews reflect individual user experiences with research compounds and are not medical advice. Results vary. These compounds are not FDA approved for human use. Peptelligent does not verify reported experiences.
Write a Review
No reviews yet. Be the first to share your experience.